Hi Tech Pharmacal (Nasdaq: HITK ) is expected to report Q2 earnings on Dec. 6. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Hi Tech Pharmacal's revenues will contract -1.9% and EPS will contract -48.1%.
The average estimate for revenue is $55.8 million. On the bottom line, the average EPS estimate is $0.56.
Last quarter, Hi Tech Pharmacal chalked up revenue of $52.0 million. GAAP reported sales were 7.4% lower than the prior-year quarter's $56.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.44. GAAP EPS of $0.44 for Q1 were 58% lower than the prior-year quarter's $1.05 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 48.7%, 1,040 basis points worse than the prior-year quarter. Operating margin was 16.3%, 1,980 basis points worse than the prior-year quarter. Net margin was 11.5%, 1,300 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $234.3 million. The average EPS estimate is $2.60.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 206 members out of 223 rating the stock outperform, and 17 members rating it underperform. Among 43 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 39 give Hi Tech Pharmacal a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hi Tech Pharmacal is outperform, with an average price target of $37.83.
More Expert Advice from The Motley Fool
The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock in our brand-new free report: "The Motley Fool's Top Stock for 2013
." I invite you to take a copy, free for a limited time. Just click here
to access the report and find out the name of this under-the-radar company.